Health News

US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences’ Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O’Shaughnessy, M.D.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Drug, Oncology, Pharmacy

Related posts

• Promising results from phase I study of Genentech’s GDC-0941 for advanced breast cancer (0)
  A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology. Read [...]
  
  
• Fourth-quarter and full-year 2009 results announced by Celsion (0)
  Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the [...]
  
  
• First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer (0)
  A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Read more [tags] Pharmacy News [/tags]
  
  
• FDA’s decision on Avastin will take away choice for many patients, says Breastcancer.org (0)
  Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA [...]
  
  
• CuraGen Updates CR011-vcMMAE Data At ASCO (0)
  CuraGen Corporation (Nasdaq: CRGN) reported three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Read more [tags] Pharmacy News [/tags]